Sacral Nerve Stimulation Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The sacral nerve stimulation market was valued at USD 1.72 billion in 2025. It is poised to grow at a CAGR of 12.50% during the forecast period of 2026-2035, and reach USD 5.59 billion by 2035. The market growth is driven by the rising prevalence of chronic pain disorders, increasing urinary and fecal incontinence cases, growing adoption of minimally invasive neuromodulation therapies, and technological advancements.

Latest News on the Sacral Nerve Stimulation Market (2026)

• In January 2026, the FDA approved Axonics PMA supplements, updating sacral neuromodulation manufacturing and components, ensuring a reliable device supply for urinary and fecal incontinence treatment globally.
• In February 2025, a study indicated that overactive bladder affects 20-24% adults globally, while urinary incontinence impacts 20-30%, significantly driving demand for advanced neuromodulation therapies.
• In March 2026, Neuspera reported a 12-month pivotal trial showing 94% responder rate using an integrated sacral neuromodulation system, demonstrating strong efficacy in urinary urge incontinence treatment outcomes.

Market Size & Forecast

• Market Size in 2025: USD 1.72 billion
• Projected Market Size in 2035: USD 5.59 billion
• Compound Annual Growth Rate (CAGR) of 2026 to 2035: 12.50%

Sacral Nerve Stimulation Market Overview

The market is growing steadily due to the rising prevalence of urinary and fecal incontinence, chronic pelvic pain disorders, and increasing demand for minimally invasive neuromodulation therapies. Technological advancements in implantable devices and expanding clinical applications are further supporting adoption. Growing awareness among patients and physicians, along with improved reimbursement coverage, is driving overall market expansion globally, while strengthening the fecal incontinence drug pipeline development landscape through ongoing research and innovation. The market reached a value of approximately USD 1.72 billion in 2025.

Sacral Nerve Stimulation Market Growth Drivers

Regulatory Approvals and Device Reliability Enhancements Supporting the Market Expansion

The increasing need for reliable implantable systems and rising procedural adoption of neuromodulation therapies are key factors supporting market expansion. These drivers are encouraging regulatory upgrades and manufacturing stability improvements. For instance, in January 2026, the FDA approved PMA supplements for Axonics sacral neuromodulation systems, including manufacturing and component updates to ensure uninterrupted device availability for urinary and fecal incontinence treatment. This development is expected to strengthen the adoption of i ntraoperative neuromonitoring -linked procedural precision and enhance procedural continuity in the forecast period.

Rising Global Burden of Overactive Bladder and Urinary Incontinence Driving Market Growth

The rising global burden of overactive bladder and urinary incontinence is a major driver of market expansion, supported by an increasing aging population, higher obesity prevalence, and growing incidence of diabetes and neurological disorders. For instance, in February 2025, it was reported that overactive bladder affects approximately 20% of adults globally (rising up to 24% in recent estimates), while urinary incontinence impacts over 20-30% of adults, with higher rates in elderly women exceeding 30% in some populations. This substantial unmet clinical burden, combined with underdiagnosis and quality-of-life impairment, is significantly driving demand for pharmacological therapies, minimally invasive procedures, and neuromodulation-based treatment options, thereby accelerating long-term market growth.

Sacral Nerve Stimulation Market Trends

Key trends shaping the market include increasing adoption of minimally invasive procedures, advancements in neuromodulation devices, and expanding clinical applications.

Long-Term Clinical Evidence and System Advancements Shaping Market Development

Growing emphasis on sustained therapeutic outcomes and improved clinical validation is shaping market development in sacral neuromodulation. These drivers are supporting increased physician confidence in implantable stimulation systems. For instance, in March 2026, Neuspera reported 12-month pivotal trial data showing a 94% responder rate with its integrated sacral neuromodulation system for urinary urge incontinence, demonstrating sustained symptom improvement and high patient retention. This development is expected to strengthen the adoption of noninvasive neuromodulation approaches and improve long-term treatment consistency in the forecast period.

Sacral Nerve Stimulation Market Segmentation

Market Breakup by Product

• Implantable SNS Devices
• External SNS Devices

Market Breakup by Type

• Electrical Muscle Stimulation
• Transcutaneous Electrical Nerve Stimulation

Market Breakup by Application

• Urinary and Fecal Incontinence
• Urge Incontinence
• Chronic Anal Fissure
• Others

Market Breakup by End User

• Hospitals
• Ambulatory Surgical Centres
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Sacral Nerve Stimulation Market Share

Urinary and Fecal Incontinence Segment Likely to Dominate the Segment by Application

The urinary and fecal incontinence segment is expected to dominate the market as it accounted for about 29% market share in the historical period. The increasing prevalence of pelvic floor disorders and the rising adoption of neuromodulation therapies are key drivers. Growing use of urinary incontinence drugs is further improving patient outcomes and strengthening clinical acceptance across healthcare systems globally.

Sacral Nerve Stimulation Market Analysis by Region

North America is expected to dominate as it accounted for about 59% market share in the historical period. Strong healthcare infrastructure, high procedural adoption, and favorable reimbursement systems are key growth drivers. The increasing adoption of neuromodulation devices is further supporting regional leadership and improving access across hospitals and specialty clinics.

Leading Players in the Sacral Nerve Stimulation Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Medtronic

Founded in 1949 and headquartered in Dublin, Ireland, Medtronic is a global medical technology leader specializing in neuromodulation therapies. Its sacral nerve stimulation portfolio includes the InterStim system used for urinary and bowel control disorders. The company advances innovation in neuromodulation therapy for chronic pelvic conditions.

Founded in 1949 and headquartered in Dublin, Ireland, Medtronic is a global medical technology leader specializing in neuromodulation therapies. Its sacral nerve stimulation portfolio includes the InterStim system used for urinary and bowel control disorders. The company advances innovation in neuromodulation therapy for chronic pelvic conditions.

Abbott Laboratories

Founded in 1888 and headquartered in Abbott Park, Illinois, USA, Abbott Laboratories is a diversified healthcare company with a strong neuromodulation segment. Its portfolio includes implantable devices for chronic pain and bladder control disorders. The company focuses on improving patient outcomes through advanced implantable neurostimulation systems.

Axonics, Inc.

Founded in 2013 and headquartered in Irvine, California, USA, Axonics, Inc. specializes in sacral neuromodulation devices. Its portfolio includes long-lasting implantable systems for urinary and bowel dysfunction. The company emphasizes minimally invasive innovation and patient comfort through next-generation sacral nerve stimulation systems.

Boston Scientific Corporation

Founded in 1979 and headquartered in Marlborough, Massachusetts, USA, Boston Scientific Corporation is a global leader in medical devices. Its neuromodulation portfolio includes the WaveWriter Alpha and spinal cord stimulation systems addressing chronic pain and pelvic disorders. The company advances innovation in neuromodulation devices for improved patient quality of life.

Other key players in the market are St. Jude Medical, Cyberonics, Neuropace, Uroplasty Inc., Codman and Shurtleff Inc., IntraPace Inc., and Synapse Biomedical.

Key Questions Answered in the Sacral Nerve Stimulation Market Report

• What was the sacral nerve stimulation market value in 2025?
• What is the sacral nerve stimulation market forecast outlook for 2026-2035?
• What major factors aid the demand for the sacral nerve stimulation market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major sacral nerve stimulation market trends?
• Which product is expected to dominate the market segment?
• Which type is expected to dominate the market segment?
• Which application is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the sacral nerve stimulation market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?